Ajanta Pharma Limited

NSEI:AJANTPHARM 株式レポート

時価総額：₹336.2b

Ajanta Pharma マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Yogesh Agrawal

最高経営責任者

₹216.0m

報酬総額

CEO給与比率57.2%
CEO在任期間17.2yrs
CEOの所有権14.5%
経営陣の平均在職期間データなし
取締役会の平均在任期間6.3yrs

経営陣の近況

Recent updates

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01
Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05
Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07
These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Oct 24
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Aug 25
Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Jul 19
Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Apr 28
A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Mar 14
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06
I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07
Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14
Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10
Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11
Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24
Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

CEO報酬分析

Ajanta Pharma の収益と比較して、Yogesh Agrawal の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2024n/an/a

₹9b

Sep 30 2024n/an/a

₹9b

Jun 30 2024n/an/a

₹9b

Mar 31 2024₹216m₹124m

₹8b

Dec 31 2023n/an/a

₹7b

Sep 30 2023n/an/a

₹7b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹156m₹112m

₹6b

Dec 31 2022n/an/a

₹6b

Sep 30 2022n/an/a

₹7b

Jun 30 2022n/an/a

₹7b

Mar 31 2022₹163m₹94m

₹7b

Dec 31 2021n/an/a

₹7b

Sep 30 2021n/an/a

₹7b

Jun 30 2021n/an/a

₹7b

Mar 31 2021₹128m₹75m

₹7b

Dec 31 2020n/an/a

₹6b

Sep 30 2020n/an/a

₹6b

Jun 30 2020n/an/a

₹5b

Mar 31 2020₹107m₹66m

₹5b

Dec 31 2019n/an/a

₹4b

Sep 30 2019n/an/a

₹4b

Jun 30 2019n/an/a

₹4b

Mar 31 2019₹99m₹61m

₹4b

Dec 31 2018n/an/a

₹4b

Sep 30 2018n/an/a

₹5b

Jun 30 2018n/an/a

₹5b

Mar 31 2018₹44m₹13m

₹5b

報酬と市場: Yogeshの 総報酬 ($USD 2.47M ) は、 Indian市場 ($USD 550.96K ) の同規模の企業の平均を上回っています。

報酬と収益: Yogeshの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Yogesh Agrawal (52 yo)

17.2yrs

在職期間

₹215,960,000

報酬

Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...

取締役

名称ポジション在職期間報酬所有権
Yogesh Agrawal
MD & Executive Director24.8yrs₹215.96m14.48%
₹ 48.7b
Rajesh Agrawal
Joint MD & Director11.8yrs₹215.96m27.48%
₹ 92.4b
Madhusudan Agrawal
Executive Vice Chairman of the Board27.2yrs₹42.04mデータなし
Ramesh Jhawar
Director of Ajanta Pharma USA Inc.no data₹25.50mデータなし
Mannalal Agrawal
Chairman of the Board45.2yrs₹777.00kデータなし
David Rasquinha
Independent Non-Executive Directorless than a yearデータなしデータなし
Medha Joshi
Independent Non-Executive Directorless than a yearデータなしデータなし
Sam Gioskos
Director of Ajanta Pharma Philippines Inc.no dataデータなしデータなし
Suttian Deerpaul
Director of Ajanta Pharma (Mauritius) Ltd.no dataデータなしデータなし
Vinayak Muzumdar
Director of Ajanta Pharma (Mauritius) Ltd.no dataデータなしデータなし
Rajesh Dalal
Independent Non-Executive Directorless than a yearデータなしデータなし
Simi Thapar
Independent Non-Executive Directorless than a yearデータなしデータなし

6.3yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: AJANTPHARMの 取締役会 は 経験豊富 であると考えられます ( 6.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/02/07 18:00
終値2025/02/07 00:00
収益2024/12/31
年間収益2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Ajanta Pharma Limited 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Rashmi Sancheti ShettyAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
null nullAsian Markets Securities Private Limited